RxDoctor Payments Data

Antonio Canero, PA

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Miami Beach, FLNPI 1902575632

Payments from drug & device makers

$2,832in general payments, 2019–2025

Across 62 payments — averaging $45.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$937
  • Edwards Lifesciences$464
  • Astellas Pharma US Inc$214
  • Sumitomo Pharma America, Inc.$198
  • Coloplast$176
  • Baxter Healthcare$143
  • plus $700 from 14 others

What the payments were for

  • Food & beverage$2,66894%
  • Education$1646%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,832 in reported general payments places this provider in the 30th percentile of 408 thoracic surgery (cardiothoracic vascular surgery) providers in Florida.

See all thoracic surgery (cardiothoracic vascular surgery) providers in Florida

Medicare billing

Part B allowed, 2024
$15,069
Medicare patients
87
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron187$117,982
GemtesaVibegron54$52,277
ElmironPentosan Polysulfate Sodium13$10,137
Tamsulosin Hcl548$7,846
Silodosin71$6,057
Alfuzosin Hcl ErAlfuzosin Hcl183$4,749
Testosterone46$3,875
Methenamine Hippurate49$3,857
Finasteride362$2,833
Tadalafil43$2,666
Tolterodine Tartrate ErTolterodine Tartrate12$1,779
Dutasteride40$1,639
Testosterone Cypionate61$1,568
Trospium Chloride14$1,389
Oxybutynin Chloride58$1,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$214$117,982187 claims
Sumitomo Pharma America, Inc.Gemtesa$198$52,27754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 thoracic surgery (cardiothoracic vascular surgery) providers in Florida.

Other thoracic surgery (cardiothoracic vascular surgery) in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →